UniQure shares plummet as FDA says inadequate clinical data for Huntington's therapy
By Christy Santhosh (Reuters) -UniQure, said on Monday the U.S. Food & Drug Administration has deemed clinical data for its gene therapy for Huntington's disease as inadequate, sending the Dutch company's U.S.-listed shares plummeting over 58% in premarket...
Reuters